Miller Kate M, Carapetis Jonathan R, Van Beneden Chris A, Cadarette Daniel, Daw Jessica N, Moore Hannah C, Bloom David E, Cannon Jeffrey W
Wesfarmers Centre of Vaccines and Telethon Kids Institute, University of Western Australia, PO Box 855, West Perth, Nedlands, WA 6872, Australia.
Perth Children's Hospital, Nedlands, WA, Australia.
EClinicalMedicine. 2022 May 20;48:101458. doi: 10.1016/j.eclinm.2022.101458. eCollection 2022 Jun.
Contemporary data for the global burden of sore throat and group A (Strep A) pharyngitis are required to understand the frequency of disease and develop value propositions for Strep A vaccines.
We used Clarivate Analytics' Web of Science platform to search WoS core collection, PubMed, Medline, data citation index, KCI-Korean Journal Database, Russian Science Citation Index, and the SciELO Citation Index for articles published between Jan 1, 2000, and Feb 15, 2021, from any country and in any language. The risk of bias was assessed using the JBI critical appraisal checklist. We used random-effects meta-analyses to pool sore throat and Strep A sore throat incidence rates from community-based studies. Our study was registered with PROSPERO (CRD42020181103).
Of 5,529 articles identified by the search strategy, 26 studies met the inclusion criteria, but only two included data to determine incidence among adults. The pooled incidence rate, calculated for children only, was 82.2 episodes per 100 child-years (95% CI 25.2-286.3, I = 100%) for sore throat (7 studies; 7,964 person years) and 22.1 episodes per 100 child-years (95% CI 14.7-33.1, I = 98%) for Strep A sore throat (9 studies; 15,696 person years). The pooled cumulative incidence rate of sore throat from five studies was 31.9 per 100 children. There was significant methodological and statistical heterogeneity among studies, and five of 26 studies had a risk of bias score less than five (range: nine [maximum score] to one).
Strep A sore throat has a considerable global burden. However, methodologically standardised studies are required to quantify that burden, analyse differences in rates between populations, and evaluate the likely impact of future Strep A vaccines.
This study was funded by Wellcome Trust 215,490/Z/19/Z.
需要有关全球咽喉痛和 A 组(A 群链球菌)咽炎负担的当代数据,以了解疾病的发生频率并为 A 群链球菌疫苗制定价值主张。
我们使用科睿唯安的 Web of Science 平台,检索了 Web of Science 核心合集、PubMed、Medline、数据引用索引、韩国科学技术院韩国期刊数据库、俄罗斯科学引文索引和科学电子图书馆引文索引,以查找 2000 年 1 月 1 日至 2021 年 2 月 15 日期间在任何国家以任何语言发表的文章。使用 JBI 批判性评价清单评估偏倚风险。我们使用随机效应荟萃分析汇总基于社区研究的咽喉痛和 A 群链球菌咽喉痛发病率。我们的研究已在国际前瞻性系统评价注册库(PROSPERO,注册号:CRD42020181103)注册。
通过检索策略识别出 5529 篇文章,其中 26 项研究符合纳入标准,但只有两项研究包含确定成人发病率的数据。仅针对儿童计算的汇总发病率为:咽喉痛为每 100 儿童年 82.2 例(95%CI 25.2 - 286.3,I² = 100%)(7 项研究;7964 人年),A 群链球菌咽喉痛为每 100 儿童年 22.1 例(95%CI 14.7 - 33.1,I² = 98%)(9 项研究;15696 人年)。五项研究的咽喉痛汇总累积发病率为每 100 名儿童 31.9 例。研究之间存在显著的方法学和统计学异质性,26 项研究中有五项偏倚风险评分低于五分(范围:九分[最高分]至一分)。
A群链球菌咽喉痛在全球负担较重。然而,需要方法学标准化的研究来量化该负担、分析人群之间发病率的差异以及评估未来A群链球菌疫苗未来可能产生的影响。
本研究由惠康信托基金资助,资助编号:215,490/Z/19/Z。